Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.34 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.33 |
| ▸ | REN known ✓ | P00797 | 1/20 | 0.33 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 5/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 4/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4131538 | 1.00 | SLC16A3 (0.36) | SLC16A3SLC16A1NAMPTSLC6A2NPC1 | |
| Fumaric Acid SCHEMBL4137854 | 0.90 | CNR1 (0.36) | SLC16A3SLC16A1NAMPTKDM4EALDH1A1 | |
| Fumaric Acid SCHEMBL4137848 | 0.90 | CNR1 (0.36) | SLC16A3SLC16A1NAMPTKDM4EALDH1A1 | |
| Fumaric Acid SCHEMBL3691572 | 0.89 | SLC16A3 (0.36) | SLC16A3SLC16A1SLC6A2NPC1HPGD | |
| Fumaric Acid SCHEMBL3691568 | 0.89 | SLC16A3 (0.36) | SLC16A3SLC16A1SLC6A2NPC1HPGD | |
| Fumaric Acid SCHEMBL4134743 | 0.87 | REN (0.36) | SLC16A3SLC16A1NAMPTNPC1HPGD | |
| Fumaric Acid SCHEMBL4134751 | 0.87 | REN (0.36) | SLC16A3SLC16A1NAMPTNPC1HPGD | |
| Fumaric Acid SCHEMBL3705567 | 0.87 | CA2 (0.37) | SLC16A3SLC16A1NPC1HPGDRAB9A | |
| Fumaric Acid SCHEMBL3705571 | 0.87 | CA2 (0.37) | SLC16A3SLC16A1NPC1HPGDRAB9A | |
| Fumaric Acid SCHEMBL4131318 | 0.85 | NAMPT (0.35) | SLC16A3SLC16A1NAMPTSLC6A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | SLC6A2 3641/4885MEN1 1910/4885KMT2A 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.